Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours

Saved in:
Bibliographic Details
Published in:Cancer treatment reviews 2003-12, Vol.29 (6), p.565-569
Main Authors: PAPE, Ulrich-Frank, WIEDENMANN, Bertram
Format: Article
Language:English
Subjects:
Antineoplastic agents
Biological and medical sciences
Chemotherapy
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Medical sciences
Pharmacology. Drug treatments
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c261t-5824ca3cb85a03945ce7473db827ac06c72ffc6ee6c90353f8d0cc1e36f4c7ad3
cites cdi_FETCH-LOGICAL-c261t-5824ca3cb85a03945ce7473db827ac06c72ffc6ee6c90353f8d0cc1e36f4c7ad3
container_end_page 569
container_issue 6
container_start_page 565
container_title Cancer treatment reviews
container_volume 29
creator PAPE, Ulrich-Frank
WIEDENMANN, Bertram
description
doi_str_mv 10.1016/j.ctrv.2003.07.002
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71324550</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71324550</sourcerecordid><originalsourceid>FETCH-LOGICAL-c261t-5824ca3cb85a03945ce7473db827ac06c72ffc6ee6c90353f8d0cc1e36f4c7ad3</originalsourceid><addsrcrecordid>eNpNkUuO1DAURSMEoouGDTBAnsAshT-xnQxbreYjtcQExpbr-aVwkdjBTtJiWSyALbAmXKpIzch60r3HVzpV9ZrRPaNMvT_tYU7rnlMq9lTvKeVPqh2TgtesU_pptaOCyloLza-qFzmfKKWdUN3z6oo1spVctbvqz41zPhyJDzOmHlMM9d_fZI4kFjbG2TskeYgPmczLGJdEphSPCXP2MRCI42QTOvLg5-__N-wQA5LDMhNcyx0Aic9ksPDj_FcfE_FjAa2lmpe0-tUOZQGZME4DXmjO54yjD3YuodG7Y4GBTeBD9G4bk19Wz3o7ZHy1vdfVtw93X28_1fdfPn6-vbmvgSs217LlDVgBh1ZaKrpGAupGC3doubZAFWje96AQFXRUSNG3jgIwFKpvQFsnrqt3F24Z_XPBPJvRZ8BhsAHjko1mgjdS0hLklyCkmHPC3kzJjzb9MoyaszRzMmdp5izNUG2KtFJ6s9GXw4jusbJZKoG3W8BmsEOfbACfH3NSFK1KiH-VO6jO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71324550</pqid></control><display><type>article</type><title>Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>PAPE, Ulrich-Frank ; WIEDENMANN, Bertram</creator><creatorcontrib>PAPE, Ulrich-Frank ; WIEDENMANN, Bertram</creatorcontrib><identifier>ISSN: 0305-7372</identifier><identifier>EISSN: 1532-1967</identifier><identifier>DOI: 10.1016/j.ctrv.2003.07.002</identifier><identifier>PMID: 14585268</identifier><identifier>CODEN: CTREDJ</identifier><language>eng</language><publisher>Oxford: Elsevier</publisher><subject>Antineoplastic agents ; Biological and medical sciences ; Chemotherapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Medical sciences ; Pharmacology. Drug treatments</subject><ispartof>Cancer treatment reviews, 2003-12, Vol.29 (6), p.565-569</ispartof><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c261t-5824ca3cb85a03945ce7473db827ac06c72ffc6ee6c90353f8d0cc1e36f4c7ad3</citedby><cites>FETCH-LOGICAL-c261t-5824ca3cb85a03945ce7473db827ac06c72ffc6ee6c90353f8d0cc1e36f4c7ad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15336963$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14585268$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>PAPE, Ulrich-Frank</creatorcontrib><creatorcontrib>WIEDENMANN, Bertram</creatorcontrib><title>Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours</title><title>Cancer treatment reviews</title><addtitle>Cancer Treat Rev</addtitle><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Chemotherapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><issn>0305-7372</issn><issn>1532-1967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNpNkUuO1DAURSMEoouGDTBAnsAshT-xnQxbreYjtcQExpbr-aVwkdjBTtJiWSyALbAmXKpIzch60r3HVzpV9ZrRPaNMvT_tYU7rnlMq9lTvKeVPqh2TgtesU_pptaOCyloLza-qFzmfKKWdUN3z6oo1spVctbvqz41zPhyJDzOmHlMM9d_fZI4kFjbG2TskeYgPmczLGJdEphSPCXP2MRCI42QTOvLg5-__N-wQA5LDMhNcyx0Aic9ksPDj_FcfE_FjAa2lmpe0-tUOZQGZME4DXmjO54yjD3YuodG7Y4GBTeBD9G4bk19Wz3o7ZHy1vdfVtw93X28_1fdfPn6-vbmvgSs217LlDVgBh1ZaKrpGAupGC3doubZAFWje96AQFXRUSNG3jgIwFKpvQFsnrqt3F24Z_XPBPJvRZ8BhsAHjko1mgjdS0hLklyCkmHPC3kzJjzb9MoyaszRzMmdp5izNUG2KtFJ6s9GXw4jusbJZKoG3W8BmsEOfbACfH3NSFK1KiH-VO6jO</recordid><startdate>20031201</startdate><enddate>20031201</enddate><creator>PAPE, Ulrich-Frank</creator><creator>WIEDENMANN, Bertram</creator><general>Elsevier</general><scope>IQODW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20031201</creationdate><title>Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours</title><author>PAPE, Ulrich-Frank ; WIEDENMANN, Bertram</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c261t-5824ca3cb85a03945ce7473db827ac06c72ffc6ee6c90353f8d0cc1e36f4c7ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Chemotherapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>PAPE, Ulrich-Frank</creatorcontrib><creatorcontrib>WIEDENMANN, Bertram</creatorcontrib><collection>Pascal-Francis</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer treatment reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>PAPE, Ulrich-Frank</au><au>WIEDENMANN, Bertram</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours</atitle><jtitle>Cancer treatment reviews</jtitle><addtitle>Cancer Treat Rev</addtitle><date>2003-12-01</date><risdate>2003</risdate><volume>29</volume><issue>6</issue><spage>565</spage><epage>569</epage><pages>565-569</pages><issn>0305-7372</issn><eissn>1532-1967</eissn><coden>CTREDJ</coden><cop>Oxford</cop><pub>Elsevier</pub><pmid>14585268</pmid><doi>10.1016/j.ctrv.2003.07.002</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0305-7372
ispartof Cancer treatment reviews, 2003-12, Vol.29 (6), p.565-569
issn 0305-7372
1532-1967
language eng
recordid cdi_proquest_miscellaneous_71324550
source ScienceDirect Freedom Collection 2022-2024
subjects Antineoplastic agents
Biological and medical sciences
Chemotherapy
Combined treatments (chemotherapy of immunotherapy associated with an other treatment)
Medical sciences
Pharmacology. Drug treatments
title Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A56%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adding%20interferon-%CE%B1%20to%20octreotide%20slows%20tumour%20progression%20compared%20with%20octreotide%20alone%20but%20evidence%20is%20lacking%20for%20improved%20survival%20in%20people%20with%20disseminated%20midgut%20carcinoid%20tumours&rft.jtitle=Cancer%20treatment%20reviews&rft.au=PAPE,%20Ulrich-Frank&rft.date=2003-12-01&rft.volume=29&rft.issue=6&rft.spage=565&rft.epage=569&rft.pages=565-569&rft.issn=0305-7372&rft.eissn=1532-1967&rft.coden=CTREDJ&rft_id=info:doi/10.1016/j.ctrv.2003.07.002&rft_dat=%3Cproquest_cross%3E71324550%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c261t-5824ca3cb85a03945ce7473db827ac06c72ffc6ee6c90353f8d0cc1e36f4c7ad3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71324550&rft_id=info:pmid/14585268&rfr_iscdi=true